The headlines are everywhere: Trump is set to reschedule marijuana from Schedule I to Schedule III. Cannabis stocks surged over 50% on the news. Industry leaders are calling it “the single most important drug policy move in decades.”
I’ll admit, my first reaction was cautiously optimistic. Finally, some movement on an issue where federal policy has been stuck in 1970 while the rest of the country moved on. But I’ve learned to look past headlines, so I started digging into what Schedule III actually means—who benefits, who doesn’t, and whether this is the reform it’s being sold as.
What I found was… complicated.
What I Expected vs. What I Found
I expected Schedule III to mean marijuana getting treated more like the relatively harmless substance most Americans already know it to be. A step toward normalcy.
Here’s what I actually found: Schedule III drugs require FDA approval to be legally prescribed. They need to be dispensed by DEA-registered entities. They have to go through the full pharmaceutical approval process—Phase II trials, Phase III trials, New Drug Applications.
Your local dispensary? Not a DEA-registered pharmacy. Those gummies and flower they sell? Not FDA-approved drugs. Under a strict reading of Schedule III, every state-legal cannabis operation would still be federally illegal.
This was the first thing that made me pause.
A Tale of Two Businesses
Let me illustrate what this might look like in practice.
Maria’s Dispensary
Maria spent three years navigating her state’s licensing process. She mortgaged her house, hired compliance consultants, installed seed-to-sale tracking, and finally opened a small dispensary in 2022. She employs eight people. She’s been paying the brutal 280E taxes that don’t let her deduct rent, payroll, or utilities—effectively paying taxes on revenue instead of profit. She’s survived, barely.
Under Schedule III, Maria gets relief from 280E. That’s real, and it matters. But she’s still not a DEA-registered pharmacy. Her products still aren’t FDA-approved. If enforcement priorities shift, she could face new legal exposure under pharmaceutical regulations. And the “pharma-grade standards” that industry analysts say are coming? Those require “major investments in infrastructure, quality systems, and regulatory readiness”—investments Maria doesn’t have capital for.
Apex Therapeutics
Apex is a pharmaceutical company that acquired a smaller cannabinoid research firm three years ago. They have FDA relationships, patent lawyers, and the infrastructure to run clinical trials. They’ve been waiting for exactly this moment.
Under Schedule III, Apex can pursue FDA approval for proprietary cannabinoid formulations. They can navigate the regulatory maze that smaller players can’t afford. They can potentially petition the FDA to crack down on “unapproved new drugs”—which is what dispensary products technically are.
I’m not saying Apex is evil or that pharmaceutical development is bad. FDA-approved medications serve important purposes. But when I look at who Schedule III is structurally designed to benefit, the Marias of the world aren’t at the top of the list.
Who Had the President’s Ear
Here’s what caught my attention about the timing of all this.
Trump had been noncommittal on rescheduling for months—saying in August it was “a very complicated subject” and that a decision would come “over the next few weeks.” Weeks turned into months. Then, this past Wednesday, he held an Oval Office meeting.
In attendance: Health Secretary RFK Jr., CMS Administrator Dr. Oz, and—notably—cannabis industry executives. Among them: the CEO of Trulieve, one of the largest multi-state cannabis operators, and a Mar-a-Lago Club member who founded a pro-cannabis advocacy group.
During that meeting, Trump called House Speaker Mike Johnson to inform him he intended to move forward with rescheduling. Johnson pushed back. Trump’s response? He let the industry executives in the room rebut Johnson’s arguments. By the end of the call, sources say, the president “appeared ready to go ahead.”
Kevin Sabet, head of an anti-legalization group, put it this way: “President Trump listened to some business associates and friends—not to the science, not to the data.”
I’m not naive enough to think any president makes policy decisions in a vacuum. But there’s something clarifying about seeing it happen so openly.
The Road Not Taken
This is where I got curious about alternatives. Why Schedule III specifically? Why not something else entirely?
Alcohol isn’t scheduled at all. Neither is tobacco. They’re regulated—heavily in some ways—but they’re not controlled substances under the DEA. They’re overseen by the Alcohol and Tobacco Tax and Trade Bureau, with states retaining significant authority over how they’re sold, taxed, and restricted.
What if marijuana had been descheduled entirely and regulated like alcohol?
Under that model, states would regulate cannabis the way they regulate beer and liquor. Some states could stay dry. Others could allow dispensaries in grocery stores. Local counties could make their own choices. The existing state-legal industry—which has already built out testing, tracking, licensing, and compliance systems—would suddenly be operating within a coherent federal framework instead of perpetual legal limbo.
What if the craft brewery model applied to cannabis? Small producers alongside large ones, with room for both?
What if Maria’s three years of compliance work actually counted for something under federal law, instead of leaving her in a gray zone while pharmaceutical companies gear up to enter a market built by people like her?
Bills have been proposed that would do exactly this—move cannabis out of the Controlled Substances Act entirely and regulate it through existing alcohol/tobacco frameworks. They haven’t passed. Instead, we’re getting Schedule III.
I’m not saying descheduling is simple or without complications. But I find myself wondering why that path wasn’t taken.
The Part That Bothers Me Most
Here’s what rescheduling definitively does not do:
It does not release anyone currently in prison for marijuana. It does not expunge anyone’s record. It does not end deportations or immigration consequences for cannabis convictions. It does not change federal employment drug testing policies.
Most federal marijuana crimes aren’t even tied to the scheduling classification. The mandatory minimums are based on quantity—pounds and plants—not which schedule the substance sits in. Moving cannabis to Schedule III doesn’t touch those sentencing thresholds.
Estimates suggest somewhere between 32,000 and 46,000 people remain incarcerated for cannabis offenses when you include state prisons, federal facilities, and local jails. Black Americans are arrested for marijuana possession at nearly four times the rate of white Americans, despite similar usage rates. Those disparities have persisted even in states that legalized.
The president has clemency power. With the stroke of a pen, federal sentences could be commuted. That’s not what’s happening here.
Rescheduling benefits companies. Descheduling would benefit companies too—but it would also create a path to address the people still locked up for something that’s now generating stock market gains.
What This Is and Isn’t
I want to be fair. Schedule III isn’t nothing.
The 280E tax relief is real and will help many cannabis businesses survive. Research barriers will be reduced, which could lead to better medical understanding of cannabinoids. The symbolic acknowledgment that marijuana has medical value matters after fifty years of the federal government insisting otherwise.
But let’s be honest about what this program is and isn’t.
It is a benefit for existing cannabis businesses and a potential windfall for pharmaceutical companies positioned to navigate FDA approval.
It isn’t legalization. It isn’t descheduling. It isn’t criminal justice reform. It isn’t a resolution of the conflict between federal law and the 38 states that have already built legal cannabis markets.
And it isn’t an accident that the version of “reform” we’re getting is the one that benefits well-capitalized operators and pharmaceutical companies while leaving incarcerated people exactly where they are.
What do you think? Is Schedule III a meaningful step forward, or a half-measure shaped more by who had access to the Oval Office than by what would actually serve the public? I’m genuinely curious what I might be missing here.